Table 4. Results of the trials... | American Society of Hematology

Table 4.

Results of the trials evaluating the role of tandem autologous stem cell transplantation (ASCT) versus ASCT followed by allogeneic reduced-intensity chemotherapy (Allo-RIC).

	Tandem Auto vs Auto/Allo-RIC
Cooperative Group	Patients	CR, %	EFS, mo	OS, mo	P	Ref.
*Only high-risk patients (high β2-microglobulin and/or del(13q); worse survival for patients with del(13q)
**Only patients with < CR/nCR after first ASCT
†Patients after first ASCT were randomized to receive maintenance versus Allo-RIC
S indicates significant P-value; NS, non-significant P-value
IFM*	166 vs 46	37 vs 55	25 vs 21	57 vs 41	NS	35
GIMEMA	82 vs 80	26 vs 55	33 vs 37	64 vs NR	S	36
PETHEMA**	82 vs 25	11 vs 40	20 vs 26	58 vs 60	NS	37
HOVON†	101 vs 115	42 vs 45	34 vs 39	63 vs 56	NS	38
EBMT	250 vs 110	41 vs 52	15 vs 36	50 vs 65	S	39

	Tandem Auto vs Auto/Allo-RIC
Cooperative Group	Patients	CR, %	EFS, mo	OS, mo	P	Ref.
*Only high-risk patients (high β2-microglobulin and/or del(13q); worse survival for patients with del(13q)
**Only patients with < CR/nCR after first ASCT
†Patients after first ASCT were randomized to receive maintenance versus Allo-RIC
S indicates significant P-value; NS, non-significant P-value
IFM*	166 vs 46	37 vs 55	25 vs 21	57 vs 41	NS	35
GIMEMA	82 vs 80	26 vs 55	33 vs 37	64 vs NR	S	36
PETHEMA**	82 vs 25	11 vs 40	20 vs 26	58 vs 60	NS	37
HOVON†	101 vs 115	42 vs 45	34 vs 39	63 vs 56	NS	38
EBMT	250 vs 110	41 vs 52	15 vs 36	50 vs 65	S	39